Intravenously Infusible Nanoparticles to Stop Bleeding and Increase Survival Following Trauma
Technical Report,30 Sep 2018,29 Sep 2019
University of Maryland College Park United States
Pagination or Media Count:
Uncontrolled bleeding is the leading cause of death in battlefield traumas. Following injury, hemostasis is established through a series of coagulatory events including platelet activation. However, with severe injuries, these processes are insufficient and result in uncontrolled bleeding. We need a therapy that that can be administered in the field to stop internal bleeding. While many agents have shown promise in small animal models, translating the work to large animal models has been exceptionally in great part because of complement activation to intravenously infused agents. We have been developing hemostatic nanoparticles for a number of years, and in the last year, we developed a formulation that does not trigger complement activation upon infusion but does lead to hemostasis in a porcine model. We propose a pilot study to test these hemostatic nanoparticles in a large animal pressure-targeted hemorrhagic shock polytrauma model that approximates injuries seen in a combat setting.
- Anatomy and Physiology